Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|November 11, 2020

ISPE Announces 2020–2021 International Board of Directors

ISPE announced its 2020–2021 International Board of Directors during the virtual 2020 ISPE Annual Meeting & Expo on Nov. 6, 2020.

The International Society for Pharmaceutical Engineering (ISPE) announced its 2020–2021 International Board of Directors during the virtual 2020 ISPE Annual Meeting & Expo on Nov. 6, 2020.

According to an ISPE press release, the new board consists of:

Officers:

  • Chair: Joanne Barrick, RPh, Advisor, Global Validation, Eli Lilly and Company
  • Vice Chair: Jörg Zimmermann, vice president, Vetter Development Service, External Affairs, Vetter Pharma Fertigung GmbH&Co KG
  • Treasurer: Michael Rutherford, executive director, Computer Systems Quality & Data Integrity, Syneos Health
  • Secretary: Scott Billman, global head of Engineering, Biogen
  • Past Chair: Frances Zipp, president and CEO, Lachman Consultant Services, Inc.

Directors Elected to a Second Term:

  • Vivianne Arencibia, independent consultant, Arencibia Quality Compliance Associates
  • Chris Chen, PhD, CEO, WuXi Biologics (Shanghai) Co., Ltd.

New Directors:

  • Nina Cauchon, PhD, director, Regulatory Affairs - CMC, Amgen Inc.
  • David Doleski, compliance head for Biologics Quality Operations, Sanofi (Appointed director)
  • Teresa Minero, founder and CEO, LifeBee - Digitalizing Life Sciences
  • Hirofumi Suzuki, PhD, senior regulatory CMC adviser, Bayer Yakuhin Ltd

Continuing Board Members:

  • Ylva Ek, chief quality officer, KeyPlants AB
  • Lou Kennedy, CEO and owner, Nephron Pharmaceuticals
  • Stephen Mahoney, JD, senior director, Global Quality & Compliance, Genentech, a member of the Roche Group
  • Alice Redmond, PhD, vice president, European Operations, CAI

Young Professionals Representative (Ex Officio):

  • John Clarke, operations lead, Pfizer

Source: ISPE​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more